Literature DB >> 33199495

CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.

Tamara L Lotan1,2,3, Emmanuel S Antonarakis2,3.   

Abstract

CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4+FOXP3- T cells were increased compared with CDK12-proficient controls.See related article by Rescigno et al., p. 566. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33199495      PMCID： PMC7855343          DOI： 10.1158/1078-0432.CCR-20-3877

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  5 in total

1.  MSH2 Loss in Primary Prostate Cancer.

Authors:  Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-08-08       Impact factor: 12.531

2.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

Authors:  Emmanuel S Antonarakis; Pedro Isaacsson Velho; Wei Fu; Hao Wang; Neeraj Agarwal; Victor Sacristan Santos; Benjamin L Maughan; Roberto Pili; Nabil Adra; Cora N Sternberg; Panagiotis J Vlachostergios; Scott T Tagawa; Alan H Bryce; Andrea L McNatty; Zachery R Reichert; Robert Dreicer; Oliver Sartor; Tamara L Lotan; Maha Hussain
Journal:  JCO Precis Oncol       Date:  2020-04-21

3.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Authors:  David A Quigley; Ha X Dang; Shuang G Zhao; Paul Lloyd; Rahul Aggarwal; Joshi J Alumkal; Adam Foye; Vishal Kothari; Marc D Perry; Adina M Bailey; Denise Playdle; Travis J Barnard; Li Zhang; Jin Zhang; Jack F Youngren; Marcin P Cieslik; Abhijit Parolia; Tomasz M Beer; George Thomas; Kim N Chi; Martin Gleave; Nathan A Lack; Amina Zoubeidi; Robert E Reiter; Matthew B Rettig; Owen Witte; Charles J Ryan; Lawrence Fong; Won Kim; Terence Friedlander; Jonathan Chou; Haolong Li; Rajdeep Das; Hui Li; Ruhollah Moussavi-Baygi; Hani Goodarzi; Luke A Gilbert; Primo N Lara; Christopher P Evans; Theodore C Goldstein; Joshua M Stuart; Scott A Tomlins; Daniel E Spratt; R Keira Cheetham; Donavan T Cheng; Kyle Farh; Julian S Gehring; Jörg Hakenberg; Arnold Liao; Philip G Febbo; John Shon; Brad Sickler; Serafim Batzoglou; Karen E Knudsen; Housheng H He; Jiaoti Huang; Alexander W Wyatt; Scott M Dehm; Alan Ashworth; Arul M Chinnaiyan; Christopher A Maher; Eric J Small; Felix Y Feng
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

4.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Authors:  Ilirjana Bajrami; Jessica R Frankum; Asha Konde; Rowan E Miller; Farah L Rehman; Rachel Brough; James Campbell; David Sims; Rumana Rafiq; Sean Hooper; Lina Chen; Iwanka Kozarewa; Ioannis Assiotis; Kerry Fenwick; Rachael Natrajan; Christopher J Lord; Alan Ashworth
Journal:  Cancer Res       Date:  2013-11-15       Impact factor: 12.701

5.  Characterizing CDK12-Mutated Prostate Cancers.

Authors:  Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 13.801
  5 in total
  2 in total

Review 1.  Exploring immunotherapy in colorectal cancer.

Authors:  Junyong Weng; Shanbao Li; Zhonglin Zhu; Qi Liu; Ruoxin Zhang; Yufei Yang; Xinxiang Li
Journal:  J Hematol Oncol       Date:  2022-07-16       Impact factor: 23.168

2.  Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient's CDK12 Mutation: A Case Report.

Authors:  Sha Zhu; Yige Bao; Linmao Zheng; Jinge Zhao; Yuntian Chen; Rui Huang; Guangxi Sun; Fengnian Zhao; Xingming Zhang; Jiayu Liang; Junru Chen; Zhipeng Wang; Yuchao Ni; Ni Chen; Pengfei Shen; Hao Zeng
Journal:  Onco Targets Ther       Date:  2022-09-02       Impact factor: 4.345
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.